Michael Bristow

Summary

Affiliation: University of Colorado Health Sciences Center
Country: USA

Publications

  1. ncbi request reprint Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators
    M R Bristow
    Division of Cardiology, University of Colorado HSC, Denver 80262, USA
    Circulation 94:2807-16. 1996
  2. ncbi request reprint Effect of baseline or changes in adrenergic activity on clinical outcomes in the beta-blocker evaluation of survival trial
    M R Bristow
    University of Colorado Health Sciences Center, Division of Cardiology, Denver, Colo 80262, USA
    Circulation 110:1437-42. 2004
  3. ncbi request reprint Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure
    Michael R Bristow
    Division of Cardiology, University of Colorado Health Sciences Center, Denver, CO 80262, USA
    N Engl J Med 350:2140-50. 2004
  4. ncbi request reprint The COMET trial
    Michael R Bristow
    Division of Cardiology, University of Colorado Health Sciences Center, B130, Room 6430, 4200 East Ninth Avenue, Denver, CO 80262, USA
    Congest Heart Fail 11:39-47. 2005
  5. ncbi request reprint Antiadrenergic therapy of chronic heart failure: surprises and new opportunities
    Michael Bristow
    University of Colorado, Denver 80262, USA
    Circulation 107:1100-2. 2003
  6. ncbi request reprint Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents
    Brian D Lowes
    Division of Cardiology and the Cardiovascular Institute, University of Colorado Health Sciences Center, Denver 80262, USA
    N Engl J Med 346:1357-65. 2002
  7. ncbi request reprint Natural history of dilated cardiomyopathy due to lamin A/C gene mutations
    Matthew R G Taylor
    University of Colorado Cardiovascular Institute, Denver, Colorado 80010, USA
    J Am Coll Cardiol 41:771-80. 2003
  8. ncbi request reprint Effects of cardiac resynchronization therapy with or without a defibrillator on survival and hospitalizations in patients with New York Heart Association class IV heart failure
    Joann Lindenfeld
    Department of Medicine, University of Colorado Health Sciences Center, 4200 E Ninth Ave, Denver, CO 80262, USA
    Circulation 115:204-12. 2007
  9. ncbi request reprint Changes in heart rate variability are correlated to hemodynamic improvement with chronic CARVEDILOL therapy in heart failure
    John R Bullinga
    Division of Cardiology, New York University, New York, NY, USA
    J Card Fail 11:693-9. 2005
  10. ncbi request reprint Selective versus nonselective beta-blockade for heart failure therapy: are there lessons to be learned from the COMET trial?
    Michael R Bristow
    Division of Cardiology, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    J Card Fail 9:444-53. 2003

Research Grants

Detail Information

Publications66

  1. ncbi request reprint Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators
    M R Bristow
    Division of Cardiology, University of Colorado HSC, Denver 80262, USA
    Circulation 94:2807-16. 1996
    ..We conducted a multicenter, placebo-controlled trial designed to establish the efficacy and safety of carvedilol, a "third-generation" beta -blocking agent with vasodilator properties, in chronic heart failure...
  2. ncbi request reprint Effect of baseline or changes in adrenergic activity on clinical outcomes in the beta-blocker evaluation of survival trial
    M R Bristow
    University of Colorado Health Sciences Center, Division of Cardiology, Denver, Colo 80262, USA
    Circulation 110:1437-42. 2004
    ....
  3. ncbi request reprint Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure
    Michael R Bristow
    Division of Cardiology, University of Colorado Health Sciences Center, Denver, CO 80262, USA
    N Engl J Med 350:2140-50. 2004
    ....
  4. ncbi request reprint The COMET trial
    Michael R Bristow
    Division of Cardiology, University of Colorado Health Sciences Center, B130, Room 6430, 4200 East Ninth Avenue, Denver, CO 80262, USA
    Congest Heart Fail 11:39-47. 2005
  5. ncbi request reprint Antiadrenergic therapy of chronic heart failure: surprises and new opportunities
    Michael Bristow
    University of Colorado, Denver 80262, USA
    Circulation 107:1100-2. 2003
  6. ncbi request reprint Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents
    Brian D Lowes
    Division of Cardiology and the Cardiovascular Institute, University of Colorado Health Sciences Center, Denver 80262, USA
    N Engl J Med 346:1357-65. 2002
    ..We tested the hypothesis that beta-blocker therapy produces favorable functional effects in dilated cardiomyopathy by altering the expression of myocardial genes that regulate contractility and pathologic hypertrophy...
  7. ncbi request reprint Natural history of dilated cardiomyopathy due to lamin A/C gene mutations
    Matthew R G Taylor
    University of Colorado Cardiovascular Institute, Denver, Colorado 80010, USA
    J Am Coll Cardiol 41:771-80. 2003
    ..We examined the prevalence, genotype-phenotype correlation, and natural history of lamin A/C gene (LMNA) mutations in subjects with dilated cardiomyopathy (DCM)...
  8. ncbi request reprint Effects of cardiac resynchronization therapy with or without a defibrillator on survival and hospitalizations in patients with New York Heart Association class IV heart failure
    Joann Lindenfeld
    Department of Medicine, University of Colorado Health Sciences Center, 4200 E Ninth Ave, Denver, CO 80262, USA
    Circulation 115:204-12. 2007
    ..We sought to examine the outcomes of NYHA class IV patients enrolled in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial to assess the potential benefits of CRT and CRT-D...
  9. ncbi request reprint Changes in heart rate variability are correlated to hemodynamic improvement with chronic CARVEDILOL therapy in heart failure
    John R Bullinga
    Division of Cardiology, New York University, New York, NY, USA
    J Card Fail 11:693-9. 2005
    ..Reduced heart rate variability (HRV) has been shown to predict mortality in heart failure (CHF). The relationship between improved cardiac function and improvement in HRV has not been previously studied...
  10. ncbi request reprint Selective versus nonselective beta-blockade for heart failure therapy: are there lessons to be learned from the COMET trial?
    Michael R Bristow
    Division of Cardiology, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    J Card Fail 9:444-53. 2003
    ....
  11. ncbi request reprint Shuttling of HDAC5 in H9C2 cells regulates YY1 function through CaMKIV/PKD and PP2A
    Carmen C Sucharov
    Division of Cardiology, School of Medicine, University of Colorado Health Sciences Center, Denver, CO 80262, USA
    Am J Physiol Cell Physiol 291:C1029-37. 2006
    ..Our results suggest that a signaling mechanism that involves CaMKIV/PKD and PP2A controls YY1 function through regulation of HDAC5 and is important in the maintenance of muscle differentiation...
  12. pmc Serial gene expression profiling in the intact human heart
    Brian D Lowes
    Division of Cardiology and the Center for Computational Pharmacology, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    J Heart Lung Transplant 25:579-88. 2006
    ..In chronic heart failure due to a dilated cardiomyopathy phenotype, the molecular bases for contractile dysfunction and chamber remodeling remain largely unidentified...
  13. ncbi request reprint Simultaneous quantification of human cardiac alpha- and beta-myosin heavy chain proteins by MALDI-TOF mass spectrometry
    Steve M Helmke
    Proteomics Facility, Box C 238, University of Colorado Health Sciences Center, 4200 East Ninth Avenue, Denver, Colorado 80262, USA
    Anal Chem 76:1683-9. 2004
    ..This method is of general applicability, especially when isoform quantification is required...
  14. ncbi request reprint Thymopoietin (lamina-associated polypeptide 2) gene mutation associated with dilated cardiomyopathy
    Matthew R G Taylor
    CU Cardiovascular Institute, University of Colorado Health Sciences Center, Denver, Colorado, USA
    Hum Mutat 26:566-74. 2005
    ..The Arg690Cys mutation altered the observed LAP2alpha interaction with A-type lamins. Our finding implicates a novel nuclear lamina-associated protein in the pathogenesis of genetic forms of dilated cardiomyopathy...
  15. ncbi request reprint The emerging pharmacogenomics of the beta-adrenergic receptors
    Matthew R G Taylor
    CU Cardiovascular Institute, Division of Cardiology, Adult Medical Genetics Program, University of Colorado Health Sciences Center, Aurora, CO, USA
    Congest Heart Fail 10:281-8. 2004
    ....
  16. ncbi request reprint Importance of right ventricular end-systolic regional wall stress in idiopathic pulmonary arterial hypertension: a new method for estimation of right ventricular wall stress
    Robert A Quaife
    Cardiac Imaging, Division of Cardiology, University of Colorado Health Sciences Center, B 120, 4200 East Ninth Avenue, Denver, Colorado 80262, USA
    Eur J Med Res 11:214-20. 2006
    ..0001). Right ventricular RWS is significantly elevated in IPAH and may provide a useful quantitative monitoring tool in patients with IPAH to assess the benefit of different therapeutic interventions and provide prognostic information...
  17. ncbi request reprint The Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial in perspective
    William H Sauer
    Division of Cardiology, University of Colorado at Denver and Health Sciences Center, Denver, CO, USA
    J Interv Card Electrophysiol 21:3-11. 2008
    ....
  18. doi request reprint Statin use is associated with improved survival in patients with advanced heart failure receiving resynchronization therapy
    Andrew D Sumner
    Division of Cardiology, Lehigh Valley Health Network, Allentown, PA 18103, USA
    Congest Heart Fail 15:159-64. 2009
    ..77; CI, 0.61-0.97; P=.03). Statin use is associated with improved survival in patients with advanced chronic HF receiving CRT. No survival benefit was seen in patients receiving statins and optimal pharmacologic therapy without CRT...
  19. ncbi request reprint Danon disease presenting with dilated cardiomyopathy and a complex phenotype
    Matthew R G Taylor
    University of Colorado at Denver and Health Sciences Center, Aurora, CO, USA
    J Hum Genet 52:830-5. 2007
    ..Furthermore, the absence of vacuolar myopathy in biopsies from young patients may not exclude Danon disease...
  20. ncbi request reprint Alterations in myocardial gene expression as a basis for cardiomyopathies and heart failure
    Matthew R Taylor
    University of Colorado Cardiovascular Institute, Denver, USA
    Novartis Found Symp 274:73-83; discussion 83-9, 152-5, 272-6. 2006
    ..The role of these alterations in gene expression in the cause, progression and interaction with therapy of heart muscle disease and heart failure is discussed...
  21. pmc Assist devices fail to reverse patterns of fetal gene expression despite beta-blockers
    Brian D Lowes
    Division of Cardiology, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    J Heart Lung Transplant 26:1170-6. 2007
    ..Our goal was to evaluate the effects of assist devices on fetal gene expression and hypoxia inducible factor-1 alpha (HIF-1 alpha), a transcriptional factor in hypoxic signaling...
  22. ncbi request reprint Prevalence of desmin mutations in dilated cardiomyopathy
    Matthew R G Taylor
    University of Colorado at Denver and Health Sciences Center, Denver, Colo, USA
    Circulation 115:1244-51. 2007
    ..Mutations in the central 2B domain of DES cause skeletal muscle disease that typically precedes cardiac involvement. However, the prevalence of DES mutations in dilated cardiomyopathy (DCM) without skeletal muscle disease is not known...
  23. ncbi request reprint Rationale and design of the enoximone clinical trials program
    Brian D Lowes
    University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    J Card Fail 11:659-69. 2005
    ..Based on these data, the ability of enoximone to deliver safe and efficacious palliative treatment of advanced/ultra-advanced chronic heart failure is being evaluated in Phase III clinical trials...
  24. ncbi request reprint Cardiac resynchronization--a heart failure perspective
    Dee Ann Rivera
    Division of Cardiology, University of Colorado HSC, Denver, Colorado 80262, USA
    Ann Noninvasive Electrocardiol 10:16-23. 2005
    ..These trials indicate that device/drug therapy is at least additive in the treatment of heart failure, and they herald a new era in the multi-modality approach to therapeutics...
  25. ncbi request reprint Relation of dose of carvedilol to reduction in QT dispersion in patients with mild to moderate heart failure secondary to ischemic or to idiopathic dilated cardiomyopathy
    Basil Pittenger
    Department of Medicine, Division of Cardiology, University of Washington, Seattle 98195 9748, USA
    Am J Cardiol 94:1459-62. 2004
    ....
  26. pmc miRNA expression in the failing human heart: functional correlates
    Carmen Sucharov
    Department of Medicine, Division of Cardiology, University of Colorado HSC, Denver, CO 80262, USA
    J Mol Cell Cardiol 45:185-92. 2008
    ..It is likely that this miR-directed reprogramming of key remodeling genes is involved in the establishment and progression of common human cardiomyopathies...
  27. ncbi request reprint A beta1-adrenergic receptor CaM kinase II-dependent pathway mediates cardiac myocyte fetal gene induction
    Carmen C Sucharov
    University of Colorado Cardiovascular Institute, Campus Box B130, UCHSC, Denver, CO 80262, USA
    Am J Physiol Heart Circ Physiol 291:H1299-308. 2006
    ..We conclude that in neonatal rat cardiac myocytes, agonist-occupied beta1-AR mobilizes Ca2+ stores to activate fetal gene induction through cAMP independent pathways that involve CaMK...
  28. ncbi request reprint Mode of death in advanced heart failure: the Comparison of Medical, Pacing, and Defibrillation Therapies in Heart Failure (COMPANION) trial
    Peter Carson
    Division of Cardiology, Veterans Affairs Medical Center, Washington, DC 20422, USA
    J Am Coll Cardiol 46:2329-34. 2005
    ....
  29. ncbi request reprint Yin Yang 1 is increased in human heart failure and represses the activity of the human alpha-myosin heavy chain promoter
    Carmen C Sucharov
    Department of Molecular, Cellular and Developmental Biology, University of Colorado, Boulder, Colorado 80309, USA
    J Biol Chem 278:31233-9. 2003
    ..These results suggest that YY1 is a negative regulator of alphaMyHC gene expression...
  30. doi request reprint An alpha2C-adrenergic receptor polymorphism alters the norepinephrine-lowering effects and therapeutic response of the beta-blocker bucindolol in chronic heart failure
    Michael R Bristow
    University of Colorado Health Sciences Center, Aurora, CO 80045, USA
    Circ Heart Fail 3:21-8. 2010
    ..This study investigated whether alpha(2C)-AR polymorphisms affect sympatholytic effects of bucindolol in patients with heart failure...
  31. ncbi request reprint Hypoplastic left heart syndrome myocytes are differentiated but possess a unique phenotype
    Teresa J Bohlmeyer
    Department of Medicine, Division of Cardiology, University of Colorado Health Sciences Center, Denver, CO 80246, USA
    Cardiovasc Pathol 12:23-31. 2003
    ..HLHS accounts for nearly 25% of cardiac deaths in the first year of life. Although much has been reported regarding diagnosis, gross morphology and surgical treatment, no information on gene expression in HLHS myocytes is available...
  32. ncbi request reprint Peak oxygen consumption and outcome in heart failure patients chronically treated with beta-blockers
    Simon F Shakar
    Denver Veterans Administration Medical Center, University of Colorado Health Sciences Center, 4200 E Ninth Avenue, Denver, CO 80262, USA
    J Card Fail 10:15-20. 2004
    ..Beta-blockers improve survival without affecting peak VO(2). We questioned the value of peak VO(2) in predicting outcome in patients treated with beta-blockers...
  33. ncbi request reprint Altered expression of endothelin receptors in failing human left ventricles
    Koji Asano
    Division of Cardiology, The Temple Hoyne Buell Heart Center Research Laboratories, University of Colorado Health Sciences Center, 4200 East Ninth Ave, Denver, CO, 80262, USA
    J Mol Cell Cardiol 34:833-46. 2002
    ..However, the behavior of endothelin receptor systems (ET(A) and ET(B)) in failing human hearts is not well understood...
  34. ncbi request reprint Angiotensin-converting enzyme DD genotype in patients with primary pulmonary hypertension: increased frequency and association with preserved haemodynamics
    William T Abraham
    Department of Medicine, University of Colorado, School of Medicine, Denver, USA
    J Renin Angiotensin Aldosterone Syst 4:27-30. 2003
    ....
  35. ncbi request reprint Quality of life and prognosis in heart failure: results of the Beta-Blocker Evaluation of Survival Trial (BEST)
    Charles W Tate
    Division of Cardiology, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    J Card Fail 13:732-7. 2007
    ..The goal of the current study was to determine the relationship between the different questionnaires, assess the effect of treatment on health status, and evaluate the association between changes in health status and prognosis...
  36. doi request reprint Increased phosphorylation-dependent nuclear export of class II histone deacetylases in failing human heart
    Mihail B Calalb
    University of Colorado Cardiovascular Institute, Denver, USA
    Clin Transl Sci 2:325-32. 2009
    ..These data provide support for decreased nuclear compartment class II HDACs in the FHH, associated with increased activities of kinases known to phosphorylate class II HDACs...
  37. pmc The PPAR-alpha activator fenofibrate fails to provide myocardial protection in ischemia and reperfusion in pigs
    Ya Xu
    Cardiology Section Veterans Affairs Medical Center, Denver, CO 80220, USA
    Am J Physiol Heart Circ Physiol 290:H1798-807. 2006
    ..Despite expression of PPAR-alpha in porcine myocardium and effects of fenofibrate on systemic metabolism, treatment with this PPAR-alpha activator does not alter myocardial metabolic or contractile responses to I/R in pigs...
  38. pmc The Ku protein complex interacts with YY1, is up-regulated in human heart failure, and represses alpha myosin heavy-chain gene expression
    Carmen C Sucharov
    Department of Molecular, Cellular and Developmental Biology, University of Colorado, Boulder, USA
    Mol Cell Biol 24:8705-15. 2004
    ..Our results suggest that Ku is an important factor in the repression of the human alphaMyHC promoter during heart failure...
  39. ncbi request reprint Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol
    Marco Metra
    Cattedra di Cardiologia, Universita di Brescia, Brescia, Italy
    J Am Coll Cardiol 40:1248-58. 2002
    ..We compared the hemodynamic effects of dobutamine and enoximone administration before and after long-term beta-blocker therapy with metoprolol or carvedilol in patients with chronic heart failure (HF)...
  40. ncbi request reprint Association of serum digoxin concentration and outcomes in patients with heart failure
    Saif S Rathore
    The Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, Conn 06520, USA
    JAMA 289:871-8. 2003
    ..The clinical outcomes associated with digoxin therapy at different serum concentrations in the DIG trial have not been assessed...
  41. ncbi request reprint Selective activation of N-acyl-D-glucosamine 2-epimerase expression in failing human heart ventricular myocytes
    Teresa Bohlmeyer
    The Heart Institute, Albany Medical College, Albany, New York 12208, USA
    J Card Fail 9:59-68. 2003
    ..NAGE is also a putative renin-binding protein. This study tested the hypothesis that NAGE is present in the human heart and that NAGE expression is increased in the failing human heart...
  42. ncbi request reprint Influence of diabetes on cardiac resynchronization therapy with or without defibrillator in patients with advanced heart failure
    Jalal K Ghali
    Wayne State University School of Medicine, Detroit, Michigan 48201, USA
    J Card Fail 13:769-73. 2007
    ..We performed a post hoc analysis to determine the influence of cardiac resynchronization therapy with a defibrillator (CRT-D) or without a defibrillator (CRT-P) on outcomes among diabetic patients with advanced heart failure (HF)...
  43. ncbi request reprint Increased reactive oxygen species production and functional alterations in antioxidant enzymes in human failing myocardium
    Flora Sam
    Myocardial Biology Unit, Boston University School of Medicine, Boston Medical Center, MA 02118, USA
    J Card Fail 11:473-80. 2005
    ..The nature of oxidative stress and the activity of antioxidant enzyme systems are incompletely characterized in the failing human heart...
  44. doi request reprint Impact of cardiac resynchronization therapy on exercise performance, functional capacity, and quality of life in systolic heart failure with QRS prolongation: COMPANION trial sub-study
    Teresa De Marco
    University of California, San Francisco Medical Center, San Francisco, CA, USA
    J Card Fail 14:9-18. 2008
    ....
  45. doi request reprint Human cardiac-specific cDNA array for idiopathic dilated cardiomyopathy: sex-related differences
    Georges E Haddad
    Department of Physiology and Biophysics, College of Medicine, Howard University, Washington, District of Columbia, USA
    Physiol Genomics 33:267-77. 2008
    ..Our observations further suggest for the first time ever novel targets for treatment of IDCM in women and men...
  46. ncbi request reprint Reciprocal modulation of mitogen-activated protein kinases and mitogen-activated protein kinase phosphatase 1 and 2 in failing human myocardium
    Catherine Communal
    Myocardial Biology Unit, Boston University School of Medicine, Boston, MA, USA
    J Card Fail 8:86-92. 2002
    ..The activity of MAPKs is regulated by dual-specificity MAPK phosphatases (MKPs). Because myocardial failure is associated with myocyte hypertrophy and apoptosis, MAPKs may play a pathophysiologic role in human myocardial failure...
  47. ncbi request reprint Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure
    Karl Swedberg
    Department of Medicine, Sahlgrenska University Hospital Ostra, Goteborg, Sweden
    Circulation 105:1797-803. 2002
    ..We investigated the dose-response relationship of a new sustained-release (SR) preparation of moxonidine and the plasma concentration of norepinephrine in patients with chronic heart failure...
  48. ncbi request reprint Microarray measurements of gene expression before and after left ventricular assist device placement
    Michael R Bristow
    J Am Coll Cardiol 41:1107-8. 2003
  49. pmc Thyroid hormone induces cardiac myocyte hypertrophy in a thyroid hormone receptor alpha1-specific manner that requires TAK1 and p38 mitogen-activated protein kinase
    Koichiro Kinugawa
    Denver Health Medical Center, Colorado 80204, USA
    Mol Endocrinol 19:1618-28. 2005
    ....
  50. ncbi request reprint Mechanisms of disease: beta-adrenergic receptors--alterations in signal transduction and pharmacogenomics in heart failure
    David S Feldman
    Davis Heart and Lung Research Institute, Division of Cardiology Medicine, Ohio State University, Columbus, OH 43210, USA
    Nat Clin Pract Cardiovasc Med 2:475-83. 2005
    ..In this review, we summarize current insights into beta-adrenergic signal-transduction pathways, the best-described beta-AR polymorphisms, and therapies that target the beta-AR pathway in HF...
  51. ncbi request reprint The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial
    Michael Domanski
    Clinical Trials Group, National Heart, Lung, and Blood Institute NIH, 6701 Rockledge Drive, Bethesda, MD 20892, USA
    J Am Coll Cardiol 42:914-22. 2003
    ..This was a retrospective analysis to determine the effect of diabetes on outcome in patients with advanced heart failure (HF), and to determine the effect of beta-blockade in patients with HF with and without diabetes mellitus...
  52. ncbi request reprint Alpha-myosin heavy chain: a sarcomeric gene associated with dilated and hypertrophic phenotypes of cardiomyopathy
    Elisa Carniel
    Familial Cardiomyopathy Registry Research Group, USA
    Circulation 112:54-9. 2005
    ..In failing human hearts, downregulation of alphaMyHC mRNA or protein has been correlated with systolic dysfunction. We hypothesized that mutations in alphaMyHC could also lead to pleiotropic cardiac phenotypes, including HCM and DCM...
  53. pmc A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure
    Stephen B Liggett
    Department of Medicine, University of Maryland, Baltimore, MD 21201, USA
    Proc Natl Acad Sci U S A 103:11288-93. 2006
    ..We conclude that beta(1)AR-389 variation alters signaling in multiple models and affects the beta-blocker therapeutic response in HF and, thus, might be used to individualize treatment of the syndrome...
  54. ncbi request reprint Cardiac resynchronization therapy and adrenergic mechanisms
    Michael R Bristow
    Am J Physiol Heart Circ Physiol 291:H2590-1. 2006
  55. ncbi request reprint Alterations in cAMP-mediated signaling and their role in the pathophysiology of dilated cardiomyopathy
    Matthew A Movsesian
    Cardiology Section, VA Salt Lake City Health Care System, Department of Internal Medicine Cardiology, University of Utah, Salt Lake City, Utah 84148, USA
    Curr Top Dev Biol 68:25-48. 2005
    ....
  56. ncbi request reprint Mechanisms and models in heart failure: the biomechanical model and beyond
    Douglas L Mann
    Winters Center for Heart Failure Research, Department of Medicine, Baylor College of Medicine, Michael E DeBakey Veterans Affairs Medical Center, Houston, TX, USA
    Circulation 111:2837-49. 2005
  57. ncbi request reprint Cost effectiveness of cardiac resynchronization therapy in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial
    Arthur M Feldman
    Department of Medicine, Jefferson Medical College, Philadelphia, Pennsylvania 19107, USA
    J Am Coll Cardiol 46:2311-21. 2005
    ....
  58. ncbi request reprint The pathophysiology of acute heart failure--it is a lot about fluid accumulation
    Marco Metra
    Am Heart J 155:1-5. 2008
  59. ncbi request reprint Cardiotrophin-1 in heart failure
    Michael R Bristow
    Circulation 106:1430-2. 2002
  60. ncbi request reprint Canonical transient receptor potential channels promote cardiomyocyte hypertrophy through activation of calcineurin signaling
    Erik W Bush
    Myogen, Inc, Westminster, Colorado 80021, USA
    J Biol Chem 281:33487-96. 2006
    ..These results define a novel role for TRPC channels in the control of cardiac growth, and suggest that a TRPC-derived pool of calcium contributes to selective activation of calcineurin in diseased heart...
  61. ncbi request reprint Increased angiotensin-(1-7)-forming activity in failing human heart ventricles: evidence for upregulation of the angiotensin-converting enzyme Homologue ACE2
    Lawrence S Zisman
    The Heart Institute and The Center for Cardiovascular Sciences, Albany Medical College, 47 New Scotland Ave, Albany, NY 12208, USA
    Circulation 108:1707-12. 2003
    ..The formation of angiotensin-(1-7) from either angiotensin (Ang) I or Ang II in failing human hearts is not well understood...
  62. ncbi request reprint Angiotensin-(1-7) formation in the intact human heart: in vivo dependence on angiotensin II as substrate
    Lawrence S Zisman
    The Heart Institute, MC 55, Albany Medical College, 47 New Scotland Ave, Albany, NY 12208, USA
    Circulation 108:1679-81. 2003
    ..Several enzymes that hydrolyze angiotensin I (Ang I) and Ang II to Ang-(1-7) have been identified, but their relative importance in the intact human heart is not known...
  63. ncbi request reprint Low-dose oral enoximone enhances the ability to wean patients with ultra-advanced heart failure from intravenous inotropic support: results of the oral enoximone in intravenous inotrope-dependent subjects trial
    Arthur M Feldman
    Department of Medicine, Jefferson Medical College, Philadelphia, PA 19107, USA
    Am Heart J 154:861-9. 2007
    ..v.) inotropic support. Chronic parenteral inotropic therapy in UA-HF is costly and requires an indwelling catheter. An effective and safe oral inotrope would have value...
  64. ncbi request reprint Loss of cardiac tetralinoleoyl cardiolipin in human and experimental heart failure
    Genevieve C Sparagna
    Department of Integrative Physiology, University of Colorado Cardiovascular Institute, University of Colorado at Boulder, Boulder, CO 80309 0354, USA
    J Lipid Res 48:1559-70. 2007
    ..This may contribute to mitochondrial respiratory dysfunction during the pathogenesis of heart failure...
  65. ncbi request reprint Drug therapy and heart failure prevention
    Jennifer V Linseman
    Circulation 107:1234-6. 2003
  66. ncbi request reprint Predictors of sudden cardiac death and appropriate shock in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Trial
    Leslie A Saxon
    Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
    Circulation 114:2766-72. 2006
    ..The factors that determine the risk for sudden death or implantable cardioverter defibrillator therapy in patients receiving cardiac resynchronization therapy (CRT) therapies are largely unknown...

Research Grants2

  1. CONTRACTILE PROTEIN EXPRESSION IN FAILING HUMAN HEART
    Michael Bristow; Fiscal Year: 2002
    ..The data generated in this proposal should determine if altered expression of contractile proteins is a molecular explanation for systolic dysfunction in the failing human heart, and if this system can be targeted therapeutically. ..
  2. Dynamic Expression Profiling in the Intact Human Heart
    Michael Bristow; Fiscal Year: 2003
    ....